Global patent index - EP 0973748 A1

EP 0973748 A1 2000-01-26 - METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES

Title (en)

METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES

Title (de)

IHRE PHARMAZEUTISCHE ANWENDUNGENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND IHRE PHARMAZEUTISCHE ANWENDUNG

Title (fr)

INHIBITEURS DE METALLOPROTEINASES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS PHARMACEUTIQUES

Publication

EP 0973748 A1 (EN)

Application

EP 98914379 A

Priority

  • US 9806365 W
  • US 82531897 A

Abstract (en)

[origin: WO9843963A1] Compounds of formula (I), wherein Y is O or S, Ar is an aryl group or a heteroaryl group, R is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or -C(O)R1, wherein R1 is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or NR2R3 wherein R2 and R3 independently are hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, and X is -NH-OH or -OH. Pharmaceutically acceptable prodrugs, salts and solvates of these compounds. Methods of inhibiting the activity of metalloproteinases by administering a compound of the formula (I) or a prodrug, salt of solvate thereof. Pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates.

IPC 1-7 (main, further and additional classification)

C07D 233/54; A61K 31/195; A61K 31/41; A61K 31/44; C07C 311/29; C07C 323/57; C07D 213/12; C07D 213/32; C07D 213/34; C07D 213/64; C07D 213/68; C07D 261/10; C07D 405/12

IPC 8 full level (invention and additional information)

A61K 31/18 (2006.01); A61K 31/198 (2006.01); A61K 31/216 (2006.01); A61K 31/4164 (2006.01); A61K 31/42 (2006.01); A61K 31/4406 (2006.01); A61K 31/4409 (2006.01); A61K 31/443 (2006.01); A61K 31/4439 (2006.01); A61P 1/02 (2006.01); A61P 9/10 (2006.01); A61P 13/00 (2006.01); A61P 17/00 (2006.01); A61P 19/02 (2006.01); A61P 19/10 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61P 43/00 (2006.01); C07C 311/29 (2006.01); C07C 323/52 (2006.01); C07C 323/59 (2006.01); C07C 323/60 (2006.01); C07D 213/32 (2006.01); C07D 213/34 (2006.01); C07D 213/643 (2006.01); C07D 213/68 (2006.01); C07D 213/70 (2006.01); C07D 233/54 (2006.01); C07D 261/08 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 213/64 (2006.01)

CPC (invention and additional information)

C07D 213/643 (2013.01); C07C 311/29 (2013.01); C07C 323/52 (2013.01); C07C 323/60 (2013.01); C07D 213/32 (2013.01); C07D 213/34 (2013.01); C07D 213/68 (2013.01); C07D 213/70 (2013.01); C07D 233/64 (2013.01); C07D 261/08 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01)

Citation (search report)

See references of WO 9843963A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9843963 A1 19981008; AU 6874498 A 19981022; AU 747280 B2 20020509; BR 9809062 A 20000801; CA 2285372 A1 19981008; EP 0973748 A1 20000126; JP 2001521504 A 20011106; NZ 338082 A 20000623

INPADOC legal status

2007-04-25 [18D] DEEMED TO BE WITHDRAWN

- Ref Legal Event Code: 18D

- Effective date: 20061003

2004-08-25 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: AGOURON PHARMACEUTICALS, INC.

- Ref Legal Event Code: RAP1

2003-04-16 [17Q] FIRST EXAMINATION REPORT

- Ref Legal Event Code: 17Q

- Effective date: 20030304

2000-01-26 [17P] REQUEST FOR EXAMINATION FILED

- Ref Legal Event Code: 17P

- Effective date: 19991028

2000-01-26 [AK] DESIGNATED CONTRACTING STATES:

- Ref Legal Event Code: AK

- Designated State(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE